Patent ID: 9522959
Filing Date: 2016-12-20
CPC Classification: A61B,A61K,A61P,C07K

Claim Text:
1. A method of treating HLA-DR-expressing B-cell lymphoma, B-cell leukemia, skin, esophageal, stomach, colon, rectal, pancreatic, lung, breast, ovarian, bladder, endometrial, cervical, testicular, melanoma, kidney, or liver cancer comprising administering to a human patient with HLA-DR-expressing B-cell lymphoma, B-cell leukemia, skin, esophageal, stomach, colon, rectal, pancreatic, lung, breast, ovarian, bladder, endometrial, cervical, testicular, kidney, or liver cancer an immunoconjugate comprising SN-38 conjugated to an hL243 (anti-HLA-DR) antibody or antigen-binding fragment thereof, wherein the immunoconjugate is administered at a dosage of between 6 mg/kg and 18 mg/kg, wherein the patient has failed to respond to at least one other therapy, prior to treatment with the immunoconjugate.